Patents by Inventor Matthew Arnold Marx

Matthew Arnold Marx has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOS1 INHIBITORS
    Publication number: 20230101312
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: February 23, 2021
    Publication date: March 30, 2023
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Aaron Craig Burns, Xiaolun Wang
  • KRAS G12D INHIBITORS
    Publication number: 20230077225
    Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: July 20, 2022
    Publication date: March 9, 2023
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • Azaquinazoline pan-KRas inhibitors
    Publication number: 20230072276
    Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: December 15, 2021
    Publication date: March 9, 2023
    Inventors: Xiaolun Wang, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • MTA-Cooperative PRMT5 Inhibitors
    Publication number: 20230054883
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: September 12, 2022
    Publication date: February 23, 2023
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • KRas G12C inhibitors
    Patent number: 11548888
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: January 10, 2023
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: Matthew Arnold Marx, James Gail Christensen, Christopher Ronald Smith, John P Fischer, Aaron Craig Burns
  • MTA-cooperative PRMT5 inhibitors
    Patent number: 11492351
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds of Formula (I) to pharmaceutical compositions comprising compounds of Formula (I) and to methods of use thereof, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions comprising those compounds.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: November 8, 2022
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
    Patent number: 11485738
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: November 1, 2022
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • MTA-cooperative PRMT5 inhibitors
    Patent number: 11479551
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds of Formula (I) to pharmaceutical compositions comprising compounds of Formula (I) and to methods of use thereof, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions comprising those compounds.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: October 25, 2022
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • KRas G12D inhibitors
    Patent number: 11453683
    Abstract: Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: September 27, 2022
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER
    Publication number: 20220274990
    Abstract: Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.
    Type: Application
    Filed: June 3, 2020
    Publication date: September 1, 2022
    Inventors: Matthew Arnold MARX, John Michael KETCHAM, Aaron Craig BURNS
  • NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS
    Publication number: 20220213097
    Abstract: Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: April 21, 2020
    Publication date: July 7, 2022
    Inventors: John Michael KETCHAM, Aaron Craig BURNS, Matthew Arnold MARX
  • TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS
    Publication number: 20220194961
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 23, 2022
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • KRAS G12C inhibitors
    Patent number: 11267812
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 8, 2022
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: John P. Fischer, Jay Bradford Fell, James F. Blake, Ronald Jay Hinklin, Macedonio J. Mejia, Erik James Hicken, Mark Joseph Chicarelli, John J. Gaudino, Guy P. A. Vigers, Laurence E. Burgess, Matthew Arnold Marx, James Gail Christensen, Matthew Randolph Lee, Pavel Savechenkov, Henry J. Zecca, Tony P. Tang
  • Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
    Patent number: 11220509
    Abstract: The present disclosure relates to compounds of Formula (I), or pharmaceutically, acceptable salts thereof, that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present disclosure relates to compounds, or pharmaceutically acceptable salts thereof pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising compounds of Formula (I), or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: January 11, 2022
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • KRAS G12C INHIBITORS
    Publication number: 20210380570
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: May 6, 2019
    Publication date: December 9, 2021
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, James F. Blake, Mark Joseph Chicarelli, Jay Bradford Fell, John P. Fischer, Erik James Hicken, Pavel Savechenkov, Tony Tang, Guy P.A. Vigers, Henry J. Zecca
  • KRAS G12C INHIBITORS
    Publication number: 20210269432
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 2, 2021
    Applicants: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: John P. FISCHER, Jay Bradford FELL, James F. BLAKE, Ronald Jay HINKLIN, Macedonio J. MEJIA, Erik James HICKEN, Mark Joseph CHICARELLI, John J. GAUDINO, Guy P.A. VIGERS, Laurence E. BURGESS, Matthew Arnold MARX, James Gail CHRISTENSEN, Matthew Randolf LEE, Pavel SAVECHENKOV, Henry J. ZECCA, Tony P. TANG
  • Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
    Patent number: 11091495
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: August 17, 2021
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • PRC2 INHIBITORS
    Publication number: 20210230168
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 29, 2021
    Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
  • KRAS G12C INHIBITORS
    Publication number: 20210230170
    Abstract: The present invention relates to compounds that, inhibit KRas G12C, In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: August 29, 2019
    Publication date: July 29, 2021
    Inventors: Matthew Arnold Marx, James F. Blake, Jay Bradford Fell, John P. Fischer, Macedonio J. Mejia
  • SOS1 INHIBITORS
    Publication number: 20210188857
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Aaron Craig Burns, Xiaolun Wang, Svitlana Kulyk, Anthony Ivetac